AbbVie eyes 2nd Rinvoq nod as it hits its marks in psoriatic arthritis
admin 31st October 2019 Uncategorised 0AbbVie blockbuster-to-be Rinvoq only just hit the scene in rheumatoid arthritis, but it’s already on its way to a second indication. Thrusday, the Illinois drugmaker said its newcomer had hit its primary endpoint in a phase 3 psoriatic arthritis (PsA) trial, topping placebo at reducing symptoms.
More: AbbVie eyes 2nd Rinvoq nod as it hits its marks in psoriatic arthritis
Source: fierce